$24.750
+0.020 (+0.08%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
該買進 SAV 股票嗎？
Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.
SAV 股價於 Monday 收在 $24.75，此前上漲 +0.08%
SAV (SAV) last closed at $24.75, gaining +0.08%. These facts feed the 1-day and 1-week SAV price prediction above.
預測驅動因素
SAV（SAV）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
SAV 季節性分析
相關文章
- How to Invest in Gold in 2026: A Guide After the Price Pullback and Fed Hike FearsGold fell about 30% from its January 2026 record as Fed hike odds rose. Learn what drives gold, ETFs vs miners, taxes, and a rules-based plan to invest in gold.
- Treasury Yields and the Stock Market: What a Near-5% 10-Year Yield Means for Investors in 2026The 10-year Treasury yield hit 5.31% in October 2026 before easing to 4.88%. Learn how Treasury yields affect stocks, which sectors react and how to plan.
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。